WEBULL
News
IPSEF
117.60
NaN%
--
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Seeking Alpha · 4h ago
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Seeking Alpha · 02/20 19:24
Genfit adds $20M as Ipsen records strong sales for liver drug
Seeking Alpha · 02/12 18:52
Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
Seeking Alpha · 02/12 06:25
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Seeking Alpha · 01/14 11:57
What To Expect From Gilead In Q3 2025
Seeking Alpha · 10/24/2025 14:56
Ipsen S.A. reports Q3 results; upgrades FY outlook
Seeking Alpha · 10/22/2025 07:09
Weekly Report: what happened at IPSEF last week (0908-0912)?
Weekly Report · 09/15/2025 09:55
Weekly Report: what happened at IPSEF last week (0901-0905)?
Weekly Report · 09/08/2025 09:56
Weekly Report: what happened at IPSEF last week (0825-0829)?
Weekly Report · 09/01/2025 09:54
Weekly Report: what happened at IPSEF last week (0818-0822)?
Weekly Report · 08/25/2025 09:58
Weekly Report: what happened at IPSEF last week (0811-0815)?
Weekly Report · 08/18/2025 09:55
Weekly Report: what happened at IPSEF last week (0804-0808)?
Weekly Report · 08/11/2025 09:58
Weekly Report: what happened at IPSEF last week (0728-0801)?
Weekly Report · 08/04/2025 10:00
Ipsen S.A. reports 1H results, FY25 guidance
Seeking Alpha · 07/31/2025 17:24
Weekly Report: what happened at IPSEF last week (0721-0725)?
Weekly Report · 07/28/2025 10:00
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Seeking Alpha · 07/24/2025 18:10
Weekly Report: what happened at IPSEF last week (0714-0718)?
Weekly Report · 07/21/2025 09:55
Weekly Report: what happened at IPSEF last week (0707-0711)?
Weekly Report · 07/14/2025 09:59
Weekly Report: what happened at IPSEF last week (0630-0704)?
Weekly Report · 07/07/2025 09:56
More
Webull provides a variety of real-time IPSEF stock news. You can receive the latest news about Ipsen Promesses through multiple platforms. This information may help you make smarter investment decisions.
About IPSEF
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.